Sickle

Sickle Cell 101 Launches Summer Sickle Cell Trait Awareness and Hydration Campaign with DPJ Football Camp Partnership

Retrieved on: 
Monday, July 17, 2023
Exercise, DPJ, NFL, Partnership, Anti-transglutaminase antibodies, Education, Life, Sickle cell trait, Dehydration, Human, Research, Parent, Athlete, Death, Exertion, Love, Sickle, Sport, Cleveland, Sickle cell disease, Cleveland Browns, Health, Malaria, Mobile phone

This is part of Sickle Cell 101's annual summer efforts to provide pertinent information and awareness on sickle cell trait, as well as the importance of hydration for all athletes, especially those with sickle cell trait.

Key Points: 
  • This is part of Sickle Cell 101's annual summer efforts to provide pertinent information and awareness on sickle cell trait, as well as the importance of hydration for all athletes, especially those with sickle cell trait.
  • DPJ continues to partner with Sickle Cell 101 in diverse capacities, including the NFL My Cause My Cleats Campaign to improve education, and research funding for sickle cell disease and sickle cell trait.
  • According to Sickle Cell 101, athletes with sickle cell trait should never be stigmatized or discouraged from participating in sports, with several prominent athletes with sickle cell trait having participated and succeeded in various sports up to the professional level.
  • The Sickle Cell Trait Awareness and Hydration Campaign by Sickle Cell 101 continues to run for the rest of the summer with various activities and digital educational events that focus on providing evidence-based information about the sickle cell trait, debunking myths, and reinforcing confidence in athletes with sickle cell trait to participate in sports while maintaining proper hydration.

Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome

Retrieved on: 
Thursday, June 22, 2023
Myelodysplastic syndrome, Exercise, Mouse, Partnership, Radiation, ASH, SCIP, Biotechnology, Gene editing, Beta thalassemia, Malignancy, Toxicity, Research, Cell, Economics, Acute myeloid leukemia, Health, Transplant, MDS, AML, Patient, Risk, Sickle, Protein engineering, Sickle cell disease, Prime editing, HSC, CD117, Therapy, Society, DSM-IV codes, Safety, Pharmaceutical industry, Vaccine

CAMBRIDGE, Mass. and BASEL, Switzerland, June 22, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, and Cimeio Therapeutics, a biotechnology company that is reinventing cell therapy through its leadership in the emerging field of epitope shielding, today announced a research collaboration to combine their respective technologies, including Prime Medicine’s Prime Editing platform and Cimeio’s Shielded Cell and Immunotherapy Pairs (SCIP) platform.

Key Points: 
  • Cimeio’s SCIP platform combined with Prime Editing may significantly improve the accessibility, eligibility and outcomes for patients who could benefit from HSC transplant.
  • These combined technologies may also enable selection of in vivo edited HSCs, which could allow for the treatment of genetic diseases without a transplant.
  • If the research collaboration is successful, the companies will grant exclusive license options to each other for their technology.
  • We look forward to partnering with the extremely talented team at Prime Medicine to advance our novel CD117 program.”

Genome Medical Supporting Beam Therapeutics on its Sickle Cell Disease Clinical Trial

Retrieved on: 
Thursday, May 25, 2023
Oxygen, Infection, SCD, Clinical trial, Research, Cell, DSM-IV codes, Pain, Genetic counseling, S, Sickle, Fetal hemoglobin, Patient, SAN, Blood, Anemia, Sickle cell disease, Death, Disease, Pharmaceutical industry, Medical imaging, Vaccine, Beam

SOUTH SAN FRANCISCO, Calif., May 25, 2023 /PRNewswire/ -- Genome Medical , the leading telehealth provider of genetic services and solutions, is teaming up with Beam Therapeutics Inc. to provide access to genetic counseling for participants in Beam's BEACON clinical trial evaluating BEAM-101 as a potential treatment for sickle cell disease (SCD).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 25, 2023 /PRNewswire/ -- Genome Medical , the leading telehealth provider of genetic services and solutions, is teaming up with Beam Therapeutics Inc. to provide access to genetic counseling for participants in Beam's BEACON clinical trial evaluating BEAM-101 as a potential treatment for sickle cell disease (SCD).
  • Through Genome Medical, Beam is sponsoring genetic counseling to provide educational resources and support to its BEACON clinical trial participants as they navigate the complexities that arise from their sickle cell diagnosis and clinical trial journey.
  • Beam will not receive any identifiable information about the patients who elect to pursue genetic counseling with Genome Medical.
  • Sickle cell disease is a group of genetic disorders that affects hemoglobin, the molecule in red blood cells that delivers oxygen to cells throughout the body.

Sickle Cell Disease Association of America to promote clinical trials

Retrieved on: 
Friday, March 17, 2023
Sickle Cell Disease Association of America, Education, Perception, Sickle cell disease, Stroke, Clinical trial, End organ damage, Quality of life, Editas Medicine, Beam Therapeutics, Organization, Jaundice, Forma, Gallstone, Death, Patient, Blood, Anemia, Sanofi, Vertex Pharmaceuticals, Research, Therapy, Chronic pain, Safety, Caregiver, Sickle, Pharmaceutical industry, Science, Pfizer

HANOVER, Md., March 17, 2023 /PRNewswire-PRWeb/ -- The Sickle Cell Disease Association of America, a national nonprofit membership organization that advocates for people affected by sickle cell, formed the Sickle Cell Disease C.A.R.E.S. Consortium, an initiative of pharmaceutical companies united to promote clinical trial participation and education.

Key Points: 
  • The Sickle Cell Disease Association of America, a national nonprofit membership organization that advocates for people affected by sickle cell, formed the Sickle Cell Disease C.A.R.E.S.
  • HANOVER, Md., March 17, 2023 /PRNewswire-PRWeb/ -- The Sickle Cell Disease Association of America, a national nonprofit membership organization that advocates for people affected by sickle cell, formed the Sickle Cell Disease C.A.R.E.S.
  • "We have an opportunity and a responsibility to change the perception of clinical trials and increase the participation of sickle cell patients in clinical trials," said Regina Hartfield, president and CEO of the Sickle Cell Disease Association of America.
  • Sickle Cell Disease Association of America advocates for people affected by sickle cell conditions and empowers community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.

Sickle Cell 101 Unveils Its Innovative Approach in Digital Advocacy for a 'Rare' Disorder Through Social Media

Retrieved on: 
Wednesday, February 1, 2023
Disease, Infection, Social media, Hospital, Education, Tissue, Empowerment, Cystic fibrosis, Sickle cell disease, Anti-transglutaminase antibodies, FDA, Degenerative disease, Patient, University, Research, LIGO Scientific Collaboration, Stroke, David Trimnel, Pain, Pharmaceutical industry, Sickle

San Jose, California--(Newsfile Corp. - February 1, 2023) - Sickle Cell 101 , a non-profit organization, is using an innovative approach of digital advocacy to provide education and patient focused research for sickle cell.

Key Points: 
  • San Jose, California--(Newsfile Corp. - February 1, 2023) - Sickle Cell 101 , a non-profit organization, is using an innovative approach of digital advocacy to provide education and patient focused research for sickle cell.
  • With a community that reaches millions on social media spread across 115 countries, Sickle Cell 101 has made a significant impact in promoting awareness of both sickle cell disease and sickle cell trait at the grassroots level through their digital platform, rich in educational and research resources.
  • "Our goal at Sickle Cell 101 is to function as a global platform to educate, engage, and empower an underserved community," says Cassandra Trimnell, Founder and Executive Director of Sickle Cell 101.
  • Sickle Cell 101 continues to seek and transform the outlook and experiences for individuals living with sickle cell disease through education and empowerment and spurring research in this area.

Dr. Niihara Meets with Local Indian Governor

Retrieved on: 
Tuesday, December 20, 2022
Blood, Patient, Back pain, Indication, African Americans, Science, K. M. Nanavati v. State of Maharashtra, Social media, Extremities, National academy, Birth, Gulf Cooperation Council, Headache, Splenomegaly, Marketing, Kingdom, Sickle cell disease, Safety, OTCQX, SCD, Sickle, Chest pain, End organ damage, Constipation, Hispanic and Latino Americans, Pain, Centers for Disease Control and Prevention, Nausea, Cough, Incidence, Disability in Canada, Sale, Blueprint, Abdominal pain, Indigestion, Pharmaceutical industry, Medicine, Vaccine, Glutamine

TORRANCE, Calif., Dec. 20, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), announced today that Dr. Yutaka Niihara, Chairman and Chief Executive Officer of the company, was hosted in Mumbai, India on December 16, 2022 by Bhagat Singh Koshyari, the Governor of the State of Maharashtra, the industrial, financial and commercial center of India. In remarks on social media, https://t.co/vTrKwVT4if, the Governor cited the more than 20 million people suffering from sickle cell disease (SCD) in his country and spoke of the discovery of Endari® that can help patients with SCD.

Key Points: 
  • Endari® is also available on an early-access basis in the Kingdom of Saudi Arabia and several European Union countries but is not yet available in India.
  • Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.
  • There are approximately 100,000 people living with sickle cell disease (SCD) in the United States and millions more globally.
  • 2Source: Committee on Addressing Sickle Cell Disease – A Strategic Plan and Blueprint for Action -- National Academy of Sciences Press, 2020.

Dr. Niihara Feted by Indian Government in Recognition of the Development of Endari®

Retrieved on: 
Monday, December 19, 2022
Blood, Glutamine, Security (finance), Patient, Back pain, Indication, African Americans, Science, Genetic disorder, Extremities, National academy, Birth, Gulf Cooperation Council, Headache, Splenomegaly, Marketing, Risk, Kingdom, State, Senior, Sickle cell disease, Safety, Ministry, World Trade Center, OTCQX, SCD, Sickle, Chest pain, Constipation, End organ damage, Hispanic and Latino Americans, Pain, Centers for Disease Control and Prevention, Nausea, Cough, 2009 Davis Cup, Incidence, Disability in Canada, Sale, Blueprint, Abdominal pain, Indigestion, Medical device, Vaccine, Medicine, Pharmaceutical industry

TORRANCE, Calif., Dec. 19, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), announced today that Dr. Yutaka Niihara, Chairman and Chief Executive Officer of the company, was feted at an event held on December 16, 2022 at the World Trade Center in Mumbai, India by the Minister of State of India, Arun Halder, in recognition of Dr. Niihara's work in developing Endari® to treat sickle cell disease (SCD). The event was hosted by Dr. Aviti Govatikar, a medical doctor and former Mrs. World.

Key Points: 
  • The event was hosted by Dr. Aviti Govatikar, a medical doctor and former Mrs. World.
  • Underprivileged tribal communities in India are disproportionately affected by SCD because of a lack of treatments and resources.
  • There are approximately 100,000 people living with sickle cell disease (SCD) in the United States and millions more globally.
  • 2Source: Committee on Addressing Sickle Cell Disease – A Strategic Plan and Blueprint for Action -- National Academy of Sciences Press, 2020.

Sickle Cell 101 Partners with NFL Player Donovan Peoples-Jones to Bolster Awareness and Research for Sickle Cell

Retrieved on: 
Wednesday, December 14, 2022
Anti-transglutaminase antibodies, Partnership, Malpractice, Donovan Peoples-Jones, AFC, Health equity, Cleveland Browns, Education, Sickle cell trait, NFL, Organization, Autoimmune hepatitis, Disease, Sickle cell disease, Social media, Patient, Week, Vaccine, Pharmaceutical industry, Research, Sickle

Sickle Cell 101 is a non profit organization that uses the innovative approach of digital advocacy to provide education and patient-focused research for sickle cell disease and sickle cell trait.

Key Points: 
  • Sickle Cell 101 is a non profit organization that uses the innovative approach of digital advocacy to provide education and patient-focused research for sickle cell disease and sickle cell trait.
  • Over the past 9 years, Sickle Cell 101 has evolved into a global brand, with platforms that advocate for all individuals affected by the disease.
  • Sickle Cell 101 is a nonprofit organization that connects, educates and empowers the worldwide sickle cell community through targeted digital engagement and data-driven initiatives.
  • As the largest global digital patient organization that specializes in sickle cell disease and sickle cell trait education, we strive to advocate for improved funding for research and health equity for the global sickle cell community.

Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting

Retrieved on: 
Sunday, December 11, 2022
Biotechnology, Technology, Health, General Health, Pharmaceutical, Oncology, Other Technology, Research, Genetics, Science, Clinical Trials, Genome, SCD, Sickle, Sickle cell trait, B cell, AS, AA, Food, Ernest, Sickle cell disease, Poster, HBS, Society, Patient, DNA, Gene editing, Knowledge, Disease, HBA, FDA, Stem cell, Reticulocyte, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Bio, SS, Bone marrow, Safety, CRISPR, Blood, Health, HSC, Gene, ASH, RNA, Graphite, HDR, Mutation, Vaccine

The novel single-cell RNA sequencing method that we developed will help us determine initial gene editing outcomes in patients treated with nula-cel, providing important preliminary information about the potential efficacy of the investigational therapy.

Key Points: 
  • The novel single-cell RNA sequencing method that we developed will help us determine initial gene editing outcomes in patients treated with nula-cel, providing important preliminary information about the potential efficacy of the investigational therapy.
  • Based on this knowledge, Graphite Bio scientists sought to develop a single-cell RNA sequencing method that could measure gene editing outcomes in reticulocytes.
  • These data support the use of this method to determine initial gene editing outcomes in patients treated with nula-cel in order to support the clinical development of this investigational therapy.
  • Graphite Bio is a clinical-stage, next-generation gene editing company driven to discover and develop cures for a wide range of serious and life-threatening diseases.

Endari® Receives Kuwaiti Marketing Authorization

Retrieved on: 
Wednesday, December 7, 2022
Indigestion, Security (finance), GCC, SCD, Sickle, Science, Chest pain, End organ damage, United Arab Emirates, National academy, Birth, Drug, Sickle cell disease, Indication, Disability in Canada, OTCQX, Cough, Blood, Patient, Kingdom, Splenomegaly, Sale, Kuwaiti, Nausea, Emma Yhnell, Headache, Hispanic and Latino Americans, Blueprint, Incidence, Pain, Back pain, Abdominal pain, Senior, Risk, Constipation, African Americans, Centers for Disease Control and Prevention, Gulf Cooperation Council, Safety, Extremities, Medication, Marketing, Pharmaceutical industry, Medicine, Vaccine, Glutamine

TORRANCE Calif., Dec. 7, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received Registration Approval from the Pharmaceutical and Herbal Medicines Registration and Control Administration (Drug and Food Control) of the Kuwaiti Ministry of Health granting marketing authorization for the commercial distribution and sale of Endari® in the country.  Kuwait is the latest Gulf Cooperation Council (GCC) country to grant full marketing approval for Endari® following approvals in the United Arab Emirates and the State of Qatar earlier this year.

Key Points: 
  • Kuwait is the latest Gulf Cooperation Council (GCC) country to grant full marketing approval for Endari following approvals in the United Arab Emirates and the State of Qatar earlier this year.
  • Endari is approved in the U.S. and elsewhere to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
  • Endari is available on an early access basis in Bahrain and the Kingdom of Saudi Arabia pending official notice of action on Emmaus's marketing authorization applications in those countries.
  • Dr. Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus, commented, "We continue to see progress in our mission to make Endari available to the many sickle cell patients in the GCC countries and are grateful to the Kuwaiti officials for this latest marketing approval."